Effects of 12 weeks of back-squat training program on jump performances and bone markers in female students

Background:The training program promoted improvements of jump abilities throughout the musculoskeletal system including bone markers.The aim of this study is to examine both the acute and chronic response of bone markers to resistance training program.Methods:Ten female students(age:18±0.7 years,body mass:63±3.6 kg;height:164±5.2 cm)participated in this study.They were recruited for a back-squat training program for 12 weeks,two days/week.The full-back squat protocol consisted of 3–5 sets×3–8 repetitions at 45–55%one repetition maximum.Testing sessions included a 5 jump test(5JT),standing long jump(SLJ),drop jump(DJ),and vertical jump(VJ).Results:Substantial improvements in all testing jumps(5JT:∆10%;P=0.000;ES=1.72;SLJ:∆7%;P=0.000;ES=1.33;DJ:∆11%;P=0.000;ES=0.72;VJ:∆20%;P=0.000;ES=1.84)were found during post program in comparison to pre-program results.Moreover,a significant change(P≤0.05)of bone markers during post-exercise compared to pre-exercise either before or after the training program.Only collagen type I carboxy-terminal peptide(CICP)levels elevated after the training program(pre-exercise only)compared to former levels.Conclusion:12 weeks of back-squat training program resulted greater acute improvements of jump abilities with adaptation in all musculoskeletal system including bone formation.

Calcium-fortified fresh milk ameliorates postmenopausal osteoporosis via regulation of bone metabolism and gut microbiota in ovariectomized rats

The aging of the global population has made postmenopausal osteoporosis prevention essential;however,pharmacological treatments are limited.Herein,we evaluate the effect of calcium-fortified fresh milk(FM)in ameliorating postmenopausal osteoporosis in a rat model established using bilateral ovariectomy.After 3 months of FM(containing vitamin D,and casein phosphopeptides,1000 mg Ca/100 g)or control milk(110 mg Ca/100 g milk)supplementation,bone changes were assessed using dual-energy X-ray absorptiometry,microcomputed tomography,and bone biomechanical testing.The results revealed that FM can regulate bone metabolism and gut microbiota composition,which act on bone metabolism through pathways associated with steroid hormone biosynthesis,relaxin signaling,serotonergic synapse,and unsaturated fatty acid biosynthesis.Furthermore,FM administration significantly increased bone mineral content and density in the lumbar spine and femur,as well as femoral compressive strength,while improving femoral trabecular bone parameters and microarchitecture.Mechanistically,we found that the effects may be due to increased levels of estrogen,bone formation marker osteocalcin,and procollagen typeⅠN-propeptide,and decreased expression of the bone resorption marker C-telopiptide and tartrate-resistant acid phosphatase 5b.Overall,the findings suggest that FM is a potential alternative therapeutic option for ameliorating postmenopausal osteoporosis.

The association between the baseline bone resorption marker CTX and incident dysglycemia after 4 years

Bone is an endocrine organ involved in modulating glucose homeostasis. The role of the bone formation marker osteocalcin （OCN） in predicting diabetes was reported, but with conflicting results. No study has explored the association between baseline bone resorption activity and incident diabetes or prediabetes during follow-up. Our objective was to examine the relationship between the baseline bone resorption marker crosslinked C-telopeptide of type I collagen （CTX） and glycemic dysregulation after 4 years. This longitudinal study was conducted in a university teaching hospital. A total of 195 normal glucose tolerant （NGT） women at baseline were invited for follow-up. The incidence of diabetes and prediabetes （collectively defined as dysglycemia） was recorded. A total of 128 individuals completed the 4-year study. The overall conversion rate from NGT to dysglycemia was 31.3%. The incidence of dysglycemia was lowest in the middle tertile [16.3% （95% confidence interval （CI）, 6.8%-30.70/0）] compared with the lower [31.0% （95% CI, 17.2%-46.1%）] and upper [46.5% （95% CI, 31.2%-62.6%）] tertiles of CTX, with a significant difference seen between the middle and upper tertiles （P = 0.002 5）. After adjusting for multiple confounding variables, the upper tertile of baseline CTX was associated with an increased risk of incident dysglycemia, with an odds ratio of 7.09 （95% CI, 1.73-28.99） when the middle tertile was the reference. Osteoclasts actively regulate glucose homeostasis in a biphasic model that moderately enhanced bone resorption marker CTX at baseline provides protective effects against the deterioration of glucose metabolism, whereas an overactive osteoclastic function contributes to an increased risk of subsequent dysglycemia.

Correlation of Serum Leptin Level with Bone Mineral Density and Bone Turnover Markers in Chinese Adolescent Dancers

Objective To investigate plasma leptin concentrations in adolescent female dancers and to determine whether leptin has some effects on their bone mineral density （BMD） and bone turnover markers. Methods Sixty dancers aged 15-17 years and 77 healthy controls were enrolled in the study. Bone mineral density （BMD） and body composition were detected by dual energy X-ray absorptiometry. Serum leptin concentrations were measured by radioimmunoassay （RIA）. Two bone turnover markers, bone-specific alkaline phosphatase （BAP） and tartrate-resistant acid phosphatase（TRACP）, were determined by ELISA. Results The dancers had a lower fat mass and a lower leptin level than the controls, while they had a relatively higher BMD of the total body and legs after adjustment for BMI and age. The levels of bone resorption and formation of markers were higher in the dancers than in the controls. Leptin was positively correlated with BMI, body weight, fat mass, and percentage of body fat. In dancers, Leptin was positively correlated with the BMD of the total body and the left leg. However, after adjustment for BMI, no correlation of serum leptin concentrations with BMD values was found in either dancers or controls. Nor correlation was found between leptin and bone turnover markers after adjustment for BMI. Conelusion The leptin profile is different between the controls and the dancers with a lower BMI and a lower fat mass. Circulating plasma leptin level depends on BMI and is not a direct determinant of BMD in Chinese adolescent dancers.

Relationship of serum GDF11 levels with bone mineral density and bone turnover markers in postmenopausal Chinese women

Growth differentiation factor 11 （GDF11） is an important circulating factor that regulates aging. However, the role of GDF11 in bone metabolism remains unclear. The present study was undertaken to investigate the relationship between serum GDF11 level, bone mass, and bone turnover markers in postmenopausal Chinese women. Serum GDF11 level, bone turnover biochemical markers, and bone mineral density （BMD） were determined in 169 postmenopausal Chinese women （47-78 years old）. GDF11 serum levels increased with aging. There were negative correlations between GDF11 and BMD at the various skeletal sites. After adjusting for age and body mass index （BMI）, the correlations remained statistically significant. In the multiple linear stepwise regression analysis, age or years since menopause, BMI, GDF11, and estradiol were independent predictors of BMD. A significant negative correlation between GDF11 and bone alkaline phosphatase （BAP） was identified and remained significant after adjusting for age and BMI. No significant correlation was noted between cross-linked N-telopeptides of type I collagen （NTX） and GDF11. In conclusion, GDF11 is an independent negative predictor of BMD and correlates with a biomarker of bone formation, BAP, in postmenopausal Chinese women. GDF11 potentially exerts a negative effect on bone mass by regulating bone formation.

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide

Daily 20-mg and once-weekly 56.5-mg teriparatide（parathyroid hormone 1–34） treatment regimens increase bone mineral density（BMD） and prevent fractures, but changes in bone turnover markers differ between the two regimens. The aim of the present study was to explain changes in bone turnover markers using once-weekly teriparatide with a simulation model. Temporary increases in bone formation markers and subsequent decreases were observed during once-weekly teriparatide treatment for 72 weeks. These observations support the hypothesis that repeated weekly teriparatide administration stimulates bone remodeling, replacing old bone with new bone and leading to a reduction in the active remodeling surface. A simulation model was developed based on the iterative remodeling cycle that occurs on residual old bone. An increase in bone formation and a subsequent decrease were observed in the preliminary simulation. For each fitted time point, the predicted value was compared to the absolute values of the bone formation and resorption markers and lumbar BMD. The simulation model strongly matched actual changes in bone turnover markers and BMD. This simulation model indicates increased bone formation marker levels in the early stage and a subsequent decrease. It is therefore concluded that remodeling-based bone formation persisted during the entire treatment period with once-weekly teriparatide.

Effect of Chongcao Bushen Capsule on bone turnover markers in patients with diabetic osteoporosis

Objective:To study the effect of Chongcao Bushen Capsules on bone turnover markers in patients with diabetic osteoporosis.Methods:107 patients with diabetic osteoporosis treated in the Hospital from December 2016 to November 2019were enrolled.They were divided into a control group(n=54)and an observation group(n=53)by random number table.The control group was treated with calcium carbonate,and the observation group was treated with Chongcao Bushen Capsules.The treatment effects,TCM syndrome scores,and bone turnover markers[including osteocalcin,type 1 procollagen amino-terminal propeptide(tP1NP),parathyroid hormone(PTH),25-hydroxyvitamin D,andβ-isomerized c-terminal peptide(β-CTx)],and the incidence of adverse reactions in the two groups were observed and compared.Results:After treatment,the total effective rate of treatment in the observation group(94.44%)was higher than that in the control group(73.58%),and the difference was statistically significant(P<0.05).The scores of symptoms including waist and knee weakness,back and waist pain,lower limb weakness,fatigue and tiredness,difficult walking and dizziness in the observation group were shown to be lower than the control group,and the difference was statistically significant(P<0.05).The levels of osteocalcin,PTH,tP1NP,andβ-CTx in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).The 25-hydroxyvitamin D in the observation group was higher than the control group,and the difference was statistically significant(P<0.05).Bone density in both male and female in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:For patients with diabetic osteoporosis,Chongcao Bushen Capsule can help improve their clinical symptoms,bone density and the level of bone turnover markers.

IMMUNOELECTRON MICROSCOPIC LOCALIZATION OF GROWTH FACTORS AND OTHER MARKERS IN HUMAN LONG－TERM BONE MARROW CULTURES

ＩＭＭＵＮＯＥＬＥＣＴＲＯＮＭＩＣＲＯＳＣＯＰＩＣＬＯＣＡＬＩＺＡＴＩＯＮＯＦＧＲＯＷＴＨＦＡＣＴＯＲＳＡＮＤＯＴＨＥＲＭＡＲＫＥＲＳＩＮＨＵＭＡＮＬＯＮＧ－ＴＥＲＭＢＯＮＥＭＡＲＲＯＷＣＵＬＴＵＲＥＳ￥ＬｉｕＪｉｅｗｅｎ；（刘杰文），ＷｙｎｔｅｒＥ...

Comparison of bone alignment and fiducial marker alignment for online cone-beam computed tomography-guided radiation therapy for prostate cancer

Objective The aim of the study was to evaluate the coverage of the prostate when prostatic implanted fiducial markers are used to verify setup of the patients in comparison to the pelvic bones while using conebeam computed tomography(CBCT). Methods Seventeen patients with prostate cancer were included. For each patient, daily online CBCT was done. CT planning was matched with CBCT with the help of fiducial markers(3–5 markers) and another matching with done the help of pelvic bony landmarks. Registration of clinical target volume(CTV) 1 including prostate plus seminal vesicles and CTV2 including prostate only was done and were used to confirm the target volume during the process of matching. Delineation of the rectum on every CBCT was done. Two automatic margin representing planning target volume(PTV) were created. PTV1 was generated by adding 1 cm in all directions(PTV1a) and 0.7 cm in the posterior direction(PTV1b). PTV2 was generated by adding 0.5 cm in all directions(PTV2a) and 0.3 cm in the posterior direction(PTV2b). PTV1a was prescribed to receive 46 Gy in conventional fractionation with a boost dose of 30 Gy to PTV1b. The same dose was prescribed to PTV2a and PTV2b. Calculation of the percentage of intersection between CTV1and CTV2 created on CBCT with the original CTV scan was done. A comparison between the two CTVs(CTV1and CTV2) mean dose and the original delineated CTV was done. Then a comparison to the mean dose of the original CTV of PTV1a, PTV2a(CTV1a and CTV2a), and for PTV1b and PTV2b(CTV1b and CTV2b). Calculation of the mean rectal dose and also V60, V70 and V74 was done on the delineated rectum on every CBCT, and then a comparison to the planned original rectal dose. Results The created CTV1and CTV2 intersection percentage with the original CTV1and CTV2 significantly increased by 85%(range, 65%–95%, P < 0.05), when fiducial markers were used. The main difference of the received mean dose was significantly less in comparison to pelvic bone alignment(0.03% to 2% vs 0.03% to 11.6% for PTV1a, P < 0.006;0.01% to 1.8% vs 0.03% to 10.2% for PTV2a, P < 0.014;0.08 to 2.11 vs 0.04 to 11.29 for PTV1b, P < 0.015 and 0.01 to 1.79 vs 0.01 to 9.69 for PTV2b, P < 0.004). With the use of less PTV margins, significant decrease of the rectal mean dose, V60, V70 and V74 by P < 0.004, P < 0.004, P < 0.0005 and P < 0.009, respectively. Reduction of the CTV1a and CTV1b mean dose by 1.13% and 0.28% in comparison to the initial CTV1a and CTV2a.Conclusion A significant improvement of prostatic cancer patients alignment when fiducial markers are used, with more homogenous dose distribution, and with significant decrease in PTV margins. The delivered rectal dose is significantly less allowing prostate dose escalation.

益肾固疏方干预老年性骨质疏松症患者骨代谢标志物的变化及临床疗效

背景:随着疾病治疗模式的改变及近年来对老年性骨质疏松症研究的深入,越来越多的研究证实中医药在防治老年性骨质疏松症方面的效果显著。目的:探讨益肾固疏方对肾虚血瘀型老年性骨质疏松症患者骨代谢标志物的影响。方法:选择2020年7月至2022年3月广西中医药大学附属瑞康医院收治的肾虚血瘀型老年性骨质疏松症患者102例,其中男32例,女70例,年龄71-93岁。采用随机数字表法将102例患者分为试验组及对照组,每组51例,对照组给予碳酸钙D3颗粒+阿仑磷酸钠片治疗,治疗组给予碳酸钙D3颗粒+阿仑磷酸钠片+益肾固疏方治疗,连续治疗3个月。治疗前及治疗3个月后,检测两组患者L_(1-4)椎体与左侧股骨颈骨密度,评估目测类比评分,检测血清骨钙素、骨桥素、Ⅰ型胶原交联C-末端肽及抗酒石酸酸性磷酸酶水平,评估中医证候积分与治疗有效率。结果与结论:①两组治疗3个月后的L1-4椎体与左侧股骨颈骨密度均高于治疗前(P<0.05),试验组治疗3个月后的L1-4椎体与左侧股骨颈骨密度均高于对照组(P<0.05);②两组治疗3个月后的目测类比评分均低于治疗前(P<0.05),试验组治疗3个月后的目测类比评分低于对照组(P<0.05);③两组治疗3个月后的血清骨钙素、骨桥素、Ⅰ型胶原交联C-末端肽及抗酒石酸酸性磷酸酶水平均较治疗前明显改善(P<0.05),试验组治疗3个月后的血清骨钙素、骨桥素水平高于对照组(P<0.05),Ⅰ型胶原交联C-末端肽及抗酒石酸酸性磷酸酶水平低于对照组(P<0.05);④两组治疗3个月后的中医证候总评分均低于治疗前,试验组治疗3个月后的中医证候总评分低于对照组;治疗3个月后,两组均未发生明显不良反应,试验组于对照组治疗总有效率分别为88.2%,70.6%,组间比较差异有显著性意义(P<0.05);⑤结果显示,益肾固疏方联合抗骨质疏松药物可通过调节骨代谢、提高骨密度、减轻患者病痛来显著改善肾虚血瘀型老年性骨质疏松症患者的临床症状,阻止疾病的进一步发展。

骨质疏松性椎体压缩骨折二级预防失败患者骨代谢指标及骨密度的变化

目的了解骨质疏松性椎体压缩骨折二级预防失败患者骨代谢指标及骨密度的特点。方法选择2015年1月至2020年1月在我院骨科因骨质疏松性椎体压缩骨折行2次或2次以上手术治疗的患者为观察组研究对象,共65例,同时选择同时期行手术治疗的非多次脊柱压缩骨折患者219例作为配对资料对照组,回顾性分析这284例患者临床资料,记录其术前骨代谢标志物水平及骨密度(bone mineral density,BMD)结果并进行两组患者间比较。结果观察组患者骨代谢标志物中人血清和血浆中的总I型前胶原氨基端肽(tP1NP)、N⁃MID骨钙素(OCN)以及血清25⁃羟维生素D(25⁃hydroxy vitamin D,25OHD)水平与对照组相比差异无统计学意义(P>0.05),骨代谢标志物I型胶原羧基端肽β特殊序列(β⁃CTX)水平明显高于对照组(P<0.05)。两组患者髋部BMD值、股骨颈BMD值差异无统计学意义(P>0.05),观察组腰椎BMD值明显低于对照组(P<0.05)。结论骨质疏松性椎体压缩骨折二级预防失败患者具有更为活跃的骨吸收状态及更低的腰椎骨密度。

类风湿关节炎血清总免疫复合物诱导破骨细胞分化引起骨质疏松的因素分析

背景:类风湿关节炎患者骨质疏松症的发生率明显增高,患者血清中存在的大量免疫复合物是否促进了骨质疏松症的发生与发展仍不明确。目的:探讨类风湿关节炎患者血清总免疫复合物与骨质疏松症的关系。方法:(1)临床试验:选择50名健康体检者(健康对照组)与50例初治型类风湿关节炎患者(类风湿关节炎组),回顾性分析两组患者的临床资料与实验室检查,比较两组血清总免疫复合物水平。将类风湿关节炎患者血清总免疫复合物与骨密度、骨转换标志物及其他临床指标进行相关性分析。(2)细胞实验:分离培养健康志愿者外周血单核细胞,分4组处理:类风湿关节炎组加入类风湿关节炎患者血清总免疫复合物悬液,正常对照组加入健康体检者血清总免疫复合物悬液,阳性对照组加入含巨噬细胞集落刺激因子与核因子κB受体活化因子配体的α-MEM培养基,阴性对照组加入α-MEM培养基。处理7 d后进行抗酒石酸酸性磷酸酶染色,观察破骨细胞形成情况。结果与结论:(1)临床试验:类风湿关节炎组患者血清总免疫复合物、血清碱性磷酸酶水平均明显高于健康体检者(P<0.01,P<0.05);Pearson相关分析结果显示,类风湿关节炎患者血清总免疫复合物与血沉(r=0.330,P=0.019)、血清碱性磷酸酶(r=0.545,P=0.001)、抗环瓜氨酸肽抗体(r=0.377,P=0.007)和Ⅰ型胶原C端肽(r=0.738,P=0.001)呈正相关关系,与腰椎骨密度(r=-0.595,P=0.001)呈负相关关系;二元Logistic回归分析结果显示,年龄[OR=1.086,95%CI(1.022,1.154),P=0.008]、抗环瓜氨酸肽抗体[OR=1.002,95%CI(0.999,1.005),P=0.035]、Ⅰ型胶原C端肽[OR=0.141,95%CI(0.015,8.900),P=0.008]和血清总免疫复合物[OR=2.895,95%CI(1.228,6.827),P=0.001]是类风湿关节炎患者骨量异常(骨量减少或骨质疏松)的影响因素;(2)细胞实验:阳性对照组、正常对照组、类风湿关节炎组可见抗酒石酸酸性磷酸酶染色阳性的破骨细胞,并且与正常对照组相比,类风湿关节炎组破骨细胞形成更多(P<0.01);(3)结果表明,血清总免疫复合物可作为预测类风湿关节炎并发骨质疏松症的潜在血清学指标,清除血清中的免疫复合物或者干预免疫复合物与其受体的结合可能成为临床预防和治疗类风湿关节炎并发骨质疏松症的有效手段。

骨代谢标志物在骨质疏松症诊治中的应用

骨质疏松性骨折是一个重要的全球健康和经济问题。目前预测骨折的方法主要有基于骨密度的测量、骨小梁评分(TBS)和基于骨脆性临床风险因素的风险计算器(FRAX)的应用。尽管采用了这些方法,仍有许多骨折未得到早期预判。因此,目前的研究重点是识别新的因素,如骨代谢标志物(bone turnover markers,BTMs)用于风险计算。BTMs测定在多种骨骼疾病的诊断与鉴别诊断、骨质疏松疾病进展的监测、骨折风险预测和药物疗效评价等方面具有重要的临床应用价值。另外,BTMs在监测骨转换和骨折风险方面的潜在应用受到影响BTMs的生理和病理生理因素的限制,这局限性导致其临床指南的纳入仍然有限。

骨密度测量仪评估老年人骨密度与参数的关系

目的:探讨骨密度测量仪评估老年人群骨密度与相关参数的关系。方法:选取2019年3月~2021年3月收治的老年髋部骨折患者100例作为骨折组,老年体检者100例作为对照组。探讨骨密度测量仪评估老年人群骨密度与相关参数的关系。结果:骨折组患者在颈骨颈、股骨转子间、腰椎、Ward’s区及腰椎部位的骨密度、FNCT及FNCT/FNW均低于对照组,FMCW值高于对照组,骨质疏松组腰椎BMD与25-(OH)D3呈正相关,与Total-P1NP、β-CTX、N-MID等骨代谢志物呈负相关。结论:通过监测骨代谢指标水平有利于辅助临床早期诊断骨质疏松症。

血清总Ⅰ型前胶原氨基端前肽和β-Ⅰ型胶原交联羧基末端肽联合检测对早期预测四肢长骨骨折延迟愈合的临床价值

目的 探讨血清总Ⅰ型前胶原氨基端前肽(PINP)和β-Ⅰ型胶原交联羧基末端肽(β-CTX)联合检测对早期预测长骨骨折延迟愈合的临床价值。方法 测定156例四肢长骨骨折患者术后1、4、8、12周时的血清PINP和β-CTX水平,根据骨折愈合情况将患者分为延迟愈合组(30例)和正常愈合组(126例),比较两组的血清PINP和β-CTX水平。采用logistic回归分析四肢长骨骨折延迟愈合的影响因素,并采用ROC曲线分析术后血清PINP和β-CTX联合检测对四肢长骨骨折延迟愈合的早期预测效能。结果 两组骨折术后血清PINP和β-CTX水平呈升高趋势,在治疗后8周达高峰,随后下降。骨折术后4、8、12周时,延迟愈合组血清PINP和β-CTX水平均低于正常愈合组,差异有统计学意义(P <0.05)。多因素logistic回归分析结果显示,术后血清PINP和β-CTX水平是四肢长骨骨折延迟愈合的独立危险因素(P <0.05)。ROC曲线显示,术后血清PINP和β-CTX联合检测预测长骨骨折延迟愈合的ROC曲线下面积(AUC)为0.861(P <0.05)。结论 术后血清PINP和β-CTX水平与四肢长骨骨折延迟愈合密切相关,二者联合检测有助于早期预测四肢长骨骨折延迟愈合。

单采血浆频次与献浆者骨密度和骨代谢相关性研究

目的了解单采血浆捐献者血清骨代谢生化标志物水平以及骨密度情况,为保障我国单采血浆捐献者健康安全提供科学依据。方法招募2022年7月1日—9月30日湖南省临武单采血浆站437名单采血浆捐献者,测定捐献者血清总钙、白蛋白、血清25-羟基维生素D(25OHD)、血清Ⅰ型原胶原N-端前肽(P1NP)、1型胶原交联羧基端肽(β-CTX)水平。采用双能X射线法对单采血浆捐献者腰椎前后位(L1-L4)骨密度、双侧股骨颈骨密度进行测量。将单采血浆捐献者按照献浆类型(新献浆者和重复献浆者)分组来评估各组间骨密度以及血清骨代谢生化标志物水平的差异。采用限制性立方样条分析献浆总次数与生化指标间的剂量反应关系,并对有显著影响的指标通过多重线性回归进行影响因素的探究。结果本研究共纳入437名研究对象,其中新献浆者187名,重复献浆者250名。新献浆者与重复献浆者两组之间不同部位骨密度及骨质疏松患病率差异均无统计学意义(P>0.05)。与新献浆者组相比,重复献浆者白蛋白及25OHD水平更低,P1NP水平更高,且均具有统计学差异。限制性立方样条结果表明,献浆总次数与25OHD及P1NP均呈非线性剂量反应关系(P<0.05)。多重线性回归结果表明,献浆频次与25OHD水平呈负相关,献浆总次数与P1NP水平呈正相关。结论单采血浆捐献不会因为长期抗凝剂的使用而影响献浆者的骨骼健康以及增加骨质疏松的风险,但会增加献浆者体内成骨活动。建议中老年献浆者适当补充维生素D。

基于4D-DIA蛋白质组学分析肺腺癌骨转移与非骨转移患者的血清差异蛋白

目的:基于深度血液4D-DIA蛋白质组学分析,寻找肺腺癌骨转移组与非骨转移组的差异蛋白,为肺腺癌骨转移诊断治疗提供新线索。方法:采用4D-DIA蛋白质组学技术,纳入6例肺腺癌非骨转移(lung adenocarcinoma non-bone metastases, LUADNBM)及6例肺腺癌骨转移(lung adenocarcinoma bone metastasis, LUADBM)患者进行血清蛋白质组学分析。以表达倍数(fold change, FC)>1.5倍(上调大于1.5倍或下调小于0.67倍)且P值<0.05(T-test或其他)为标准,得到比较组间的上调、下调蛋白质数目。对两组间的可定量蛋白进行基因集富集分析(gene set enrichment analysis,GSEA)。应用String网站和R语言对差异蛋白进行主成分分析(principal component analysis,PCA)、基因本体论(gene ontology,GO)分析和KEGG(Kyoto encyclopedia of genes and genomes)通路数据库分析。结果:LUADNBM组与LUADBM组间比较发现2 585个可定量蛋白,其中18个差异蛋白。GSEA结果显示,可定量蛋白主要富集在真核翻译延伸阶段、SARS-CoV-2主要翻译机制通路(P<0.05)。PCA结果显示,差异蛋白可明显区分LUADNBM与LUADBM患者。GO分析结果表明,差异蛋白主要富集在高尔基管腔和细胞外基质,在皮肤硫酸盐蛋白聚糖的生物合成和代谢过程以及硫酸软骨素的分解代谢和生物合成中发挥重要作用;KEGG结果表明:上调蛋白主要富集在近端小管碳酸氢盐回收、胆汁分泌、N-聚糖生物合成、胰岛素分泌、醛固酮的合成和分泌等通路;下调蛋白主要富集在神经退行性疾病的途径,如阿尔茨海默病、亨廷顿病、帕金森病、脊髓小脑性共济失调等。结论:肺腺癌骨转移组与非骨转移组蛋白存在明显差异,通过发现新型蛋白标志物为早期筛查诊断骨转移提供新线索。

藏药二十五味鬼臼丸对去势大鼠血清性激素及骨转换标志物的影响

目的探究藏药二十五味鬼臼丸对去势大鼠血清性激素及骨转换标志物的影响。方法将36只SD大鼠随机分为给药组、模型组及假手术组,给药组和模型组做卵巢摘除手术。术后两周开始灌胃给药,给药组予二十五味鬼臼丸混悬液(400mg/kg),模型组和假手术组予蒸馅水,每日1次,持续12周。用微计算机断层扫描技术(Micro-CT)检测右侧股骨近端结构、扫描电子显微镜(SEM)观测股骨微结构;以酶联免疫吸附试验(ELISA)检测大鼠血清骨吸收标志物抗酒石酸酸性磷酸酶5b(TRAP5b),血清骨形成标志物骨碱性磷酸酶BALP,血清E,、LH、FSH。结果Micro-CT和SEM显示,藏药二十五味鬼臼丸能显著改善去势骨质疏松症大鼠模型的股骨近端骨微结构和骨小梁密度;Pearson相关性分析显示,血清E_(2)水平与TRAP5b水平呈负相关,与BALP水平呈正相关;血清FSH、LH水平与BALP水平呈负相关。结论藏药二十五味鬼臼丸对去势大鼠血清性激素的影响:升高血清E,激发机体下丘脑-垂体-卵巢轴(HPO)上游的LH、FSH反馈调节;对骨转换标志物的影响:降低血清TRAP5b含量同时升高血清BALP含量,可改善骨代谢失衡,进而改善骨微结构。

消增强骨丸对肝肾阴虚型骨质疏松症患者骨转换标志物的影响

目的:探讨消增强骨丸对肝肾阴虚型骨质疏松症患者骨转换标志物的影响。方法:选取80例肝肾阴虚型骨质疏松症患者,随机分成观察组和对照组,每组40例。对照组予以碳酸钙D3片、骨化三醇软胶囊及阿仑膦酸钠片,观察组在对照组的基础上服用消增强骨丸,两组均治疗6个月。治疗后比较两组腰椎骨密度(bone mineral density,BMD)、髋部BMD、血清25-(OH)VitD、Ⅰ型胶原羧基端肽β特殊序列(β-C-terminal telopeptide of typeⅠcollagen,β-CTX)、Ⅰ型原胶原氨基端延长肽(propeptide of type 1 procollagen,PINP)、骨碱性磷酸酶(bone specific alkaline phosphatase,BALP)、骨钙素(bone gla protein,BGP)及腰部视觉模拟评分法(visual analogue scale,VAS)评分。结果:两组治疗前腰椎BMD、髋部BMD、25-(OH)VitD、β-CTX、PINP、BALP、BGP、腰部VAS评分之间比较,差异无统计学意义(P>0.05)。治疗后观察组腰椎BMD、髋部BMD、25-(OH)VitD、PINP、BALP、BGP较对照组增高,观察组β-CTX、腰部VAS评分较对照组降低(P<0.05)。结论:消增强骨丸治疗肝肾阴虚型骨质疏松症患者疗效可靠,可以影响骨转换标志物,提高骨密度,缓解患者腰部疼痛症状。

血清WISP1水平与绝经后骨质疏松症的相关性研究

目的:观察血清Wnt1诱导信号通路蛋白1(Wnt1-inducible-signaling pathway protein 1,WISP1)水平在绝经后骨质疏松症(postmenopausal osteoporosis,PMOP)患者中的变化,并分析其与骨密度(bone mineral density,BMD)各项骨代谢指标的相关性,探索WISP1在PMOP发生发展中的作用。方法:选取2020年5月─2022年8月在苏州大学附属第一医院健康管理中心进行健康体检的绝经后女性共148例,利用双能X线吸收仪(dual-energy X-ray absorptiometry,DXA)骨密度仪测量腰椎骨密度,根据不同骨量分为骨量正常组(T值≥-1.0),骨量减少组(-2.5<T值<-1.0),骨质疏松组(T值≤-2.5),分别采集临床基本资料,测定骨代谢指标及血清WISP1质量浓度,经SPSS软件进行统计处理。结果:骨质疏松组及骨量减少组的血清WISP1质量浓度均显著高于骨量正常组(均P<0.05)。血清WISP1水平与成骨标志物碱性磷酸酶、总Ⅰ型前胶原氨基端肽密切相关。结论:WISP1可能通过刺激成骨反应参与PMOP的病理生理过程。